Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells $1,060,800.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 40,000 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $26.52, for a total value of $1,060,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gregory Bailey also recently made the following trade(s):

  • On Thursday, January 4th, Gregory Bailey sold 50,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $28.71, for a total value of $1,435,500.00.
  • On Wednesday, December 20th, Gregory Bailey sold 39,430 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.31, for a total value of $1,037,403.30.
  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.48, for a total value of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.02, for a total value of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.92, for a total value of $533,952.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) opened at $31.24 on Friday. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $17.00 and a 1-year high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. equities analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 EPS for the current year.

A number of analysts have recently issued reports on BHVN shares. Morgan Stanley restated an “overweight” rating and issued a $38.00 target price (down previously from $47.00) on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Monday, December 4th. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, December 11th. Canaccord Genuity assumed coverage on Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Needham & Company LLC cut their price objective on Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $36.14.

Several large investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new position in Biohaven Pharmaceutical during the third quarter worth $119,000. Nationwide Fund Advisors acquired a new position in Biohaven Pharmaceutical during the third quarter worth $214,000. American International Group Inc. acquired a new position in Biohaven Pharmaceutical during the third quarter worth $251,000. State of Wisconsin Investment Board acquired a new position in Biohaven Pharmaceutical during the third quarter worth $262,000. Finally, Susquehanna International Group LLP acquired a new position in Biohaven Pharmaceutical during the third quarter worth $302,000. Institutional investors and hedge funds own 47.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/21/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-sells-1060800-00-in-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply